TrialJournal of gynecologic oncology2019

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.

Peey Sei Kok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.